- Details
- Zach Klaassen speaks with Abhishek Srivastava about the significance of germline and genomic testing in advanced prostate cancer. Dr. Srivastava elaborates on his recent publication, which aims to improve the penetration of such testing in urology, particularly in community practices. He emphasizes the importance of cascade testing for identifying actionable mutations and influencing treatment opt...
|
- Details
- In this discussion, Andrea Miyahira speaks with Ping Mu about his group's paper. The research focuses on the role of SYNCRIP in controlling APOBEC-driven mutagenesis in prostate cancer. Dr. Mu explains that the loss of SYNCRIP leads to a break in the mechanism controlling this mutagenesis driver, resulting in prostate cancer gaining resistance to AR therapy. The conversation highlights the tumor h...
|
- Details
- Neal Shore, Sarah Nielsen, and David Wise discuss broadening access to germline testing for prostate cancer patients. Reflecting on their collective efforts, including the PROCLAIM Trial and an editorial on Universal Genetic Germline Testing for Hereditary Cancer Syndromes, they emphasize democratizing genetic testing and universal accessibility. The conversation delves into the underutilization o...
|
- Details
- Alicia Morgans host Fatima Karzai and Rana McKay to explore the National Cancer Institute Natural History Study. This study focuses on prostate cancer patients with unusual mutations and exceptional responses to treatments, aiming to understand their disease progression over time. The trial, conducted across multiple sites including UCSD, follows participants longitudinally, particularly those wit...
|
- Details
- Elena Castro joins Alicia Morgans in a discussion on the clinical trial landscape for metastatic castration-resistant prostate cancer. When seeing a patient, Elena considers prior therapies and genetic testing, noting BRCA1 and BRCA2 alterations being investigated earlier provide an opportunity to treat patients with different PARP inhibitors. Drs. Morgans and Castro highlight the use of radiophar...
|
- Details
- In this discussion between Alicia Morgans and Kim Chi, they discuss the challenges, controversies, and opportunities of PARP inhibitor combinations with androgen receptor signaling inhibitors. Dr. Kim Chi summarized the MAGNITUDE trial that studied metastatic CRPC patients who received ARPI or abiraterone vs. abiraterone plus niraparib. The trial's pre-screening process selected patients with homo...
|
- Details
- Alan Bryce joins Alicia Morgans in a discussion on the interim overall survival data from TRITON3, a Phase 3 study comparing rucaparib to physician's choice of therapy in metastatic castration-resistant prostate cancer associated with homologous recombination deficiency. Eligible patients had received at least one prior androgen receptor pathway inhibitor, were chemotherapy-naïve in the CRPC setti...
|
- Details
- This video provides a comprehensive overview of Decipher Prostate, a genomic test used to personalize treatment for prostate cancer. In diagnosing prostate cancer, doctors traditionally assess the risk of the disease spreading based on three factors: the amount of disease in the prostate, the Gleason score, and a PSA blood test. However, these factors may lead to over or under-treatment of individ...
|
- Details
- Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial's primary endpoint was radio...
|
- Details
- Alicia Morgans converses with Noel Clarke about the significance of biomarkers in castration-resistant prostate cancer. Dr. Clarke highlights the clinical importance of recognizing diversity among prostate cancer patients, particularly considering age and associated comorbidities. Noting that many patients, especially from socially deprived backgrounds, face challenges due to comorbidities, he und...
|
